Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences Inc (NQ: CRBU )

4.740 +0.050 (+1.07%)
Streaming Delayed Price Updated: 2:33 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Caribou Biosciences Inc

< Previous 1 2 3 Next >
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... 
Via FinancialNewsMedia
Exposures Product Safety
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
Ongoing complete response at 15 months reported in first patient treated with CB-010 
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
From Caribou Biosciences, Inc.
Via Business Wire
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
From Caribou Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.